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Abstract
Background: The aim of this study was to compare the cost effectiveness of the current Irish programme of
universal BCG vaccination of infants versus a programme which considered selectively vaccinating high risk infants
using decision analytical modelling.
Methods: The efficacy of the BCG vaccine was re-evaluated to inform a decision analytical model constructed to
follow a birth cohort of vaccinated and unvaccinated infants over a 15 year time horizon. The number of life years
gained (LYG) was the primary outcome measure and this was compared to the net cost of the vaccination strategies.
Results: In the base case analysis, the incremental cost effectiveness ratios (ICERs) for the universal strategy and
selective strategy vs no vaccination were €204,373/LYG and €143,233/LYG respectively. When comparing the
incremental difference in moving from the universal to the selective strategy, the selective strategy costs
€1,055,692 less per 4.8 life years lost per birth cohort. One way sensitivity analyses highlighted that a move from
the universal to the selective strategy was particularly sensitive to the estimate of vaccine efficacy against deaths,
the cost of administering the vaccine and the multiplier used to apportion risk of contracting tuberculosis.
Probabilistic analysis suggested that a move from a universal based strategy to a selective based strategy could
be deemed cost effective (probability of cost effectiveness is 76.8 %).
Conclusion: The results of the study support the protective effect of the BCG vaccine in infants and quantified the
cost effectiveness of the current BCG vaccination strategy and the decremental difference in moving to a selective
strategy. This analysis highlights that the additional protection offered by the universal vaccination strategy is small
compared to that of the selective strategy. Consideration should therefore be given to the implementation of a
selective vaccination strategy, and diverting resources to improve TB case management and control.
Keywords: BCG vaccine, Paediatric tuberculosis, Vaccine efficacy, Cost effectiveness, Neonatal vaccination
Background
As the incidence of TB continues to decline in high and
middle income countries and because of the conflicting
data on its protective efficacy, a valid and pressing ques-
tion is whether BCG vaccination should be discontinued
or targeted at certain groups, known to have a higher
risk of contracting infection. The International Union
Against Tuberculosis and Lung Diseases (IUATLD) rec-
ommends that routine vaccination be discontinued when
the average annual notification rate of sputum smear
positive pulmonary TB is 5 per 100,000 population or
less during the previous 3 years [1].
As well as the IUATLD criteria, there are additional
considerations, such as economic analysis and societal
preference, which should be addressed when deciding
to modify or stop a universal BCG programme. Ireland
and Portugal remain the only countries in Western
Europe implementing universal BCG vaccination pro-
grammes. France revised its approach to the use of the
BCG vaccine, firstly in 2004, when revaccination with
BCG ceased [2] and then in 2007 when routine vaccin-
ation of all school children ceased and a more targeted
approach to vaccination was introduced [3]. The na-
tional policy in Finland was changed in 2005, whereby
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the universal vaccination policy was changed to a tar-
geted approach of high risk infants [4]. Likewise in the
UK, a review and revision of the BCG vaccination pol-
icy lead to the implementation of a selective vaccin-
ation strategy of high risk groups in favour of the
universal schools programme which had been in place
since the 1950s. Some countries with low rates of TB,
such as Sweden and Switzerland, discontinued their
universal BCG vaccination strategies many years ago
[5]. Japan has also reappraised the value of routine
BCG vaccination in the prevention of TB [6]. These
policy differences are mainly related to differences in
opinion about the efficacy of the vaccine and local vari-
ations in TB epidemiology.
In 2012 the National Immunisation Advisory Commit-
tee (NIAC) commenced an economic analysis of the
existing universal BCG vaccine programme in Ireland.
The aim of the assessment was to examine the cost ef-
fectiveness of the current BCG vaccination programme
of infants using revised estimates of vaccine efficacy and
to quantify the incremental difference in moving to a se-
lective based strategy, which identified and vaccinated




Prior to commencing the evaluation, the scope of the
analysis was agreed with an expert advisory group. The
base-case parameters for the model were established and
the most appropriate data inputs were collected for the
model.
Perspective
The analysis was undertaken from the perspective of
the Health Service Executive (HSE), i.e., the healthcare
payer. Therefore only direct medical costs were in-
cluded in the evaluation. Costs associated with prod-
uctivity changes due to parental time off work were
included in a separate scenario analysis.
Vaccination strategies
For the universal BCG strategy, it is assumed that a birth
cohort of infants (n = 72,410) is vaccinated with a cover-
age rate of 80 % (of the birth cohort). The size of the
birth cohort in this analysis (n = 72,410) is based on the
population estimates in Ireland for 2011.
For the selective strategy, the target group of high-risk
children was estimated to be 11.7 % of the birth cohort
with a coverage rate of 44 %. The definition of “high-
risk’” was infants with at least one parent from a high
TB incidence country (≥ 40 cases per 100,000 persons)
and was based on information taken from the “Growing
up in Ireland” study which showed that 10.7 % of fathers
and 12.7 % of mothers of the infant cohort (born be-
tween December 2007 and May 2008) were born in
Eastern Europe, Africa and the “Rest of the World”-re-
gions which could be considered areas of high TB
endemnicity [7].
The children in the high risk group are assumed also
to have a risk of TB which is three times (x3) higher
than the 88.3 % of children in the remaining low-risk
group. This assumption is based data provided in the
HPSC Report on the Epidemiology of Tuberculosis [8].
The overall incidence is a weighted average between the
two groups, and thus the increased risk in the high risk
group is matched by a decreased risk in the remainder
of the population.
It is assumed that the vaccine would be administered
to the neonates before they reach 3 months of age and
would be delivered in the community setting.
Model structure
A decision analytic model was constructed to follow a
birth cohort of vaccinated and unvaccinated individuals
from birth over a 15 year period. The model is based on
a series of health states (i.e., pulmonary TB, extrapul-
monary TB, meningeal TB and death) that an individual
can occupy at a given point in time and it is run in an-
nual cycles. The model estimates the number of cases of
pulmonary TB, extrapulmonary TB and TB meningitis
averted in the birth cohort of 72,410 infants. Age-
specific background mortality was based on life tables
from the Irish Central Statistics Office [9]. The number
of life years gained (LYG) from the vaccination pro-
grammes was the primary health outcome measure, and
these were compared to the net cost i.e., the additional
cost of universal or selective vaccination minus the ex-
pected savings from reduced use of healthcare resources,
due to a reduction in the burden of TB disease. The
model was fitted with local cost, resource use and epi-
demiological data.
In the evaluation, cases of pulmonary TB, extrapul-
monary TB, and meningeal TB are always initially man-
aged as inpatients, and this reflects current clinical
practice in Ireland. TB meningitis can lead to long term
complications (hearing loss, focal neurological deficits,
development delay, epilepsy) which are also incorporated
into the analysis. The analysis was performed in MS
Excel 2010.
Comparator
The vaccination strategies were compared to no vaccin-
ation, i.e., BCGuniversal vs BCGno vaccination and BCGselective
vs BCGno vaccination, before comparing the incremental
difference in moving from a universal strategy to a se-
lective strategy.
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Model inputs
Vaccine efficacy
Several systematic reviews to date conclude that BCG
vaccination of infants is very effective in preventing
miliary TB and TB meningitis in children [10]. One
meta-analysis conducted in the USA [11] provided evi-
dence for a protective effect of the BCG vaccine against
pulmonary TB, TB deaths, TB meningitis, laboratory
confirmed TB cases and disseminated TB. In 1995
Colditz and colleagues (13) reviewed the results of 5
randomised control trials and 11 case control studies.
They estimated the protective effect of the BCG vaccine
for preventing pulmonary TB, TB deaths, TB meningi-
tis, laboratory confirmed TB cases and disseminated
TB. Trunz and colleagues [12] re-evaluated BCG effi-
cacy against childhood TB meningitis and miliary TB
by adding seven more published investigations to earlier
meta-analyses of published case-control studies [10, 11]. A
total of 18 case-control studies provided revised estimates
of efficacy for TB meningitis and miliary TB, which are
similar to earlier published estimates [10, 11, 13].
In Ireland, the Health Protection Surveillance Centre
(HPSC) documents all cases of notified TB. In addition
to documenting cases, other information such as age,
gender, local health office/county, country of birth, BCG
vaccination status, presence of BCG scar, and treatment
outcome is recorded. It therefore serves as a reliable
source to estimate the effectiveness of the BCG vaccin-
ation in the Irish population. To this end, a retrospective
evaluation of TB cases, stratified according to BCG sta-
tus from the years 2002 to 2011 was conducted. The
analysis was fitted in R (version 2.15.2) to combine this
Irish data with data from Colditz [11] and Trunz [12].
Resulting risk ratios provide estimates of vaccine efficacy
for the Irish population aged 0-15 years strengthened by
international estimates. A forest plot of the results is
shown (Fig. 1), illustrating the impact different data
sources have on the revised combined estimates.
Vaccine uptake
Not all local health offices report their BCG vaccine up-
take rates to the HPSC. The mode of delivery also var-
ies across the country with approximately 75 % of all
BCG vaccinations being performed in local health of-
fices and the remainder (25 %) being done in maternity
hospitals (National Immunisation Office (NIO), per-
sonal communication). For the purposes of the current
study, it was assumed that the vaccine uptake in the
base case analysis would be approximately 80 % for the
universal strategy and was varied by 75–95 % in the
sensitivity analysis. These figures were based on expert
clinical opinion (from the NIO) and the latest HPSC
immunization statistics [14].
For the selective strategy, it was assumed that the
vaccine uptake in the base case analysis would be ap-
proximately 44 % and was varied by 38–50 % in the
sensitivity analysis. These figures were based on experi-
ence from France [15], where, following a change in
their vaccination schedule to a selective based strategy,
reported uptake rates of lower magnitude than those
experienced for the universal strategy. Experience from
other low incidence countries, showed similar evidence
for a reduced uptake rate for a selective based strategy,
e.g., Sweden reported a vaccine uptake rate of less than
2 % in 1976 a year after changing to a selective based
strategy [5].
Incidence of childhood TB
In the southern area of Ireland, a universal neonatal
BCG vaccination was offered in Cork up to 1972 when a
decision was taken to discontinue the vaccine for a var-
iety of reasons. This small cohort, together with the in-
formation provided by the HPSC, therefore provided a
reliable source to estimate the incidence of childhood
TB in a non-vaccinated Irish population. Annualized in-
cidence rates were calculated for each TB health state,
for each year between 0 and 15 years, and these were
used as the basis to build the model. In a separate sce-
nario analysis, which examined the effect of the vaccine
up to 25 years, annualized incidence rates from those
aged 16–25 years were used (Table 1).
Fig. 1 Estimates of vaccine efficacy from meta-analysis and combined
results used in the model. Shown are risk ratios and 95 % confidence
intervals. The size of the red squares indicates the relative influence of
the trial on the combined estimate; trials of large sample size will have
a higher impact compared to trials of smaller sample size. The black
diamond illustrates the combined estimate for each outcome; its width
is a measure of the associated uncertainty
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Mortality data
There were no recorded deaths due to TB in the 0–15 year
old population, so a case fatality rate (CFR) of 0.8 % (based
on UK Surveillance data from 2001 to 2010, compiled by
the Health Protection Agency, UK [16]) was applied.
Long term complications of TB meningitis
There is a wide range of possible long-term sequelae fol-
lowing meningitis and the analysis is restricted to four
main complications: hearing loss, developmental delay,
focal neurological deficits andepilepsy. The probability of
these events occurring was derived from published studies.
In 1964, Todd and Neville [17] estimated the incidence
of hearing loss and epilepsy attacks. They combined the
results of their own study with those of Wasz-Hockert &
Donner [18], Lorber [19], Voljavec et al. [20], Pohitonova
[21] and Lapides [22]. From these 6 studies they com-
bined information on the incidence of sequelae in 855
children who had survived an attack of meningeal TB.
The estimates for hearing loss and epilepsy attacks were
7 and 7.6 % respectively. Lorber [19] estimated the inci-
dence of cognitive impairment at 50 %. Schoeman [23]
estimated that focal neurological deficits occurred in
25 % of cases analysed. The probabilities of long-term




Cost estimates are explained in terms of healthcare re-
source use (i.e., vaccination costs and direct medical
costs) and unit cost data.
Vaccination costs
Vaccination cost estimates were obtained from the NIO
of the HSE. The cost of vaccination includes the cost of
Table 1 Annualised incidence rate of TB clinical syndromes and mortality by age in a non-vaccinated cohort of Irish children
2002-2010
Age group Annualised incidence




TB per 1000 population
Annualised incidence
rate of TB Meningitis
per 1000 population
Under 1 year 0.015 0.000 0.015
1 year 0.000 0.015 0.000
2 years 0.196 0.075 0.000
3 years 0.133 0.015 0.000
4 years 0.030 0.015 0.000
5 years 0.031 0.015 0.000
6 years 0.016 0.000 0.000
7 years 0.000 0.015 0.015
8 years 0.031 0.015 0.000
9 years 0.031 0.000 0.000
10 years 0.049 0.032 0.000
11 years 0.032 0.016 0.000
12 years 0.017 0.033 0.017
13 years 0.032 0.000 0.000
14 years 0.063 0.031 0.000
15 years 0.061 0.000 0.000
16 years 0.031 0.031 0.000
17 years 0.047 0.032 0.000
18 years 0.074 0.044 0.000
19 years 0.056 0.028 0.000
20 years 0.053 0.040 0.000
21 years 0.130 0.026 0.000
22 years 0.079 0.039 0.000
23 years 0.103 0.039 0.013
24 years 0.075 0.000 0.000
25 years 0.108 0.060 0.012
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the vaccine as well as the cost of administration of the
vaccine. The vaccine ingredient costs are calculated as
80 or 50 % of the cost of distributed vaccine in 2012
for the universal and selective strategies respectively
(Personal communication with NIO). The cost of admin-
istration is based on an administration fee of €27.75 and
€50 per infant, for the universal strategy and selective
strategies respectively. The higher fee for the selective
strategy reflects the difficulty that may be present in iden-
tifying those at high risk. Changes to the administration
fee are explored in the sensitivity analysis.
Direct medical costs
Due to the lack of published Irish cost data, and the
time constraints with conducting specific micro-costing
studies, an assessment of resource use items associated
with diagnosis and treatment of each of the health
states (pulmonary TB, extrapulmonary TB and TB
meningitis) were obtained by the evaluation team with
local clinical experts. The costs associated with contact
tracing per primary case of TB and diagnosing and
treating 50 % of those contacts for latent TB were
added to the direct medical costs of pulmonary TB,
extrapulmonary TB and TB meningitis. Costs of con-
tact tracing and latent TB are based on 9.4 contacts
per TB case and are shown in Table 2. The costs of
managing the long-term sequelae of meningitis were
also included and the overall cost shown in Table 2. A
comprehensive list of resource utilisation and unit cost
data used to estimate direct medical costs of latent TB,
pulmonary TB, extrapulmonary TB, TB meningitis and
long term sequelae of meningitis are provided in Add-
itional files 1, 2, 3, 4 and 5 respectively.
Unit cost data
Unit costs for inpatient procedures were obtained from
2010 Diagnosis Related Group (DRG) data provided by
the National Casemix Unit of the HSE [24]. Unit costs
for tuberculin skin tests were obtained from the Finance
department of a local university teaching hospital (St.
James’s Hospital, Dublin). Costs of antimicrobial therapy
were obtained from the Pharmacy department of St.
James’s Hospital Dublin. Every effort was made to in-
corporate Irish unit cost data. However, where data were
not available it was adapted from the UK. UK costs were
converted to euro using the exchange rate (€1.18) pub-
lished by the Central Bank of Ireland and all costs were
inflated to 2012 euro, using the consumer price index
for health inflationary unit (105.6).
Adverse events
The model uses the incidence rate of severe adverse
events (1 in 1000) reported in the summary of product
characteristics for the BCG vaccine [25]. Following review
of all local reports [26–33] as well as international reports
[34–36] published in the literature, none of the reports in-
dicate that the rate is higher than this. The estimate of 1
in 1000 is applied only in the first year for the cohort as
the literature indicates that the median onset of adverse
effects ranges from 30 days to 4 months [32–35]. This rate
is varied in the sensitivity analysis from > 1/10,000 to < 1/
100 which is within the rates reported in the summary of
product characteristics [25].
Time horizon
The analytic time frame of the study was fifteen years in
the base case analysis given the current paucity of data on
the duration of vaccine protection beyond this time [37].
Outcome measure
The main outcome measure in the analysis was cost per
LYG.
Discounting
An annual discount rate of 5 % was applied to both costs
and consequences in the economic model, consistent with




One-way sensitivity analysis was undertaken for the base
case analysis. Ranges for the parameter values used are
shown in Table 2.
Probabilistic sensitivity analysis
A probabilistic sensitivity analysis was also conducted
whereby all parameters were varied simultaneously. One
thousand simulated combinations of the parameters
were drawn and for each of these combinations a cost
per LYG was estimated.
Scenario analyses
Long term effect of vaccination
 A scenario analysis was conducted which examined
the effect of vaccination up to 25 years. To do this,
incidence data was gathered from those aged 16
to 25 years from non-vaccinated and vaccinated
cohorts respectively and rates of vaccine efficacy
against the TB health states (Protective effect: 0.55
95 % CI 0.31 to 0.77) and against TB death (Protective
effect: 0.44 95 % CI−0.22 to 0.70) were applied [39].
Vaccinating a birth cohort-the societal perspective
 A scenario analysis was conducted whereby the
indirect costs due to TB were included in the analysis.
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Table 2 Summary of parameter estimates, with base case values, range, distributions and sources





Incidence of TB: see Table 1.
Vaccine efficacy Probability
Pulmonary TB 0.74 0.45–0.87 Beta [11, 12] Irish HPSC
data 2002–2011
Extrapulmonary TB 0.84 0.66–0.92 Beta
TB Meningitis 0.73 0.66–0.79 Beta
TB Deaths 0.67 0.19–0.86 Beta
Scenario Analysis: 0–25 year old cohort
Vaccine Efficacy (against TB) 0.55 0.31–0.77 Beta [39]
Vaccine Efficacy (against TB death) 0.44 −0.22–0.75 Beta [39]
Direct costs- children (average cost per acute episode per child)
Pulmonary TB €8,153 +/−20 % Log Normal NCPE 2012
Extrapulmonary TB €12,223 +/−20 % Log Normal NCPE 2012
TB Meningitis €15,752 +/−20 % Log Normal NCPE 2012
Contact tracing per primary case of TB €4,248 +/−20 % Log Normal HSE East 2012
Latent TB per primary case of TB €4,203 +/−20 % Log Normal NCPE 2012
Long term costs due to meningitis
(over 15 years)
€36,225.39 +/−20 % Log Normal NCPE 2012
Vaccine Ingredient costs (per strategy)
Universal (80 % of the cost of distributed
vaccine in 2012)
€155,215 +/−20 % Fixed National Immunisation
Office / HSE procurement
Selective (50 % of the cost of distributed
vaccine in 2012)
€97,010
Administration cost per dose National Immunisation
Office / HSE procurement
Universal €27.75 per dose Point
Selective €50 per dose +/−50 %
Vaccine coverage Uniform National Immunisation
Office [14, 15]
Universal 80 % 79–97 %
Selective 44 % 38–50 %
Case Fatality Rate (CFR) 0.8 % 0.5–1.1 % Beta [16]
Discount rate for costs and benefits 4 % 0–6 % Point [38]
Incidence of adverse events 1/1000 > 1/10,000 to < 1/100 Beta multiplier [25]
Costs per treatment for adverse event €2,895 +/−20 % Log Normal NCPE 2012
Multiplier used for high risk population 3-fold x 2–x 8 Uniform (on log scale) [8]
Proportion of birth cohort estimated to
be at high risk
11.7 % 10.7–12.7 % Uniform [7]
Indirect Costs
Value of work loss/week for parent
of children with an adverse event or TB
€476.40 [40]
Percentage of parents taking time
of work
Not included 42 % Not included [41]
Number of days of work lost 4
NCPE National Centre for Pharmacoeconomics, HSE East: Health Service Executive East
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This analysis included the value of work lost per
week [40] for a parent of a child with TB or an
adverse event due to vaccination. This was based
on the work of Roberts et al., [41], which stated
that 42 % of parents would take time off work
and an assumption that the number of work
days lost is four.
Results
Baseline costs and effects
In the base case scenario, the model estimates the num-
ber of cases of pulmonary TB, extrapulmonary TB and
TB meningitis averted in a birth cohort of 72,410 infants
under the three scenarios (Table 3).
For the universal strategy, the total cost of the BCG
vaccine, including an administration fee of €27.75 per
dose, would be approximately €1.7 million per year for
a birth cohort of 72,410 infants. For the selective strat-
egy, the total cost of the BCG vaccine, including an
administration fee of €50 per dose, would be approxi-
mately €280,207 per year. The vaccine ingredient costs
are calculated as 80 or 50 % of the cost of distributed
vaccine in 2012 for the universal and selective strategies
respectively.
The cost of diagnosing and treating TB disease was es-
timated to decrease by €848,199 and €160,945 in the
universal and selective vaccinated cohorts respectively
due to cost savings from avoided TB disease among the
vaccinated cohorts (Table 4).
The costs of treating adverse events due to vaccin-
ation were also estimated at €134,161 and €10,607
for the universal and selective strategies respectively.
Baseline incremental cost-effectiveness ratios
The base case ICERs, when comparing the universal
and selective vaccination strategies to not vaccinating
are €204,373/LYG and €143,233/LYG respectively.
When comparing the incremental difference in moving
from the universal to the selective strategy, the select-
ive strategy costs €1,055,692 less per 4.8 life years lost
per birth cohort (Table 5).
Sensitivity analyses
One-way
The main drivers of uncertainty in the model for the
analysis of the incremental difference in going from a
universal strategy to a selective strategy were as follows
(Fig. 2);
 Vaccine efficacy against deaths
When this parameter was varied by its 95 % CI
estimates, it resulted in the selective strategy costing
€1,055,692 less with 1.4 and 6.2 life years lost for
the lower and upper CIs, respectively.
 Cost of vaccine administration
When this parameter was varied by its 95 % CI
estimates, it resulted in the selective strategy loosing
4.83 life years and costing €259,182 and €1,475,670
less for the lower and upper CIs, respectively.
 Multiplier
When a risk of x2 is apportioned to the high risk
population the selective strategy costs €1,012,728
less with a loss of 5.2 life years. When a risk of x8 is
apportioned to the high risk population the selective
strategy costs €1,270,508 less with a loss of 2.9 life
years.
Probabilistic sensitivity analysis
A probabilistic analysis was run (1,000 simulations) and
the incremental difference for selective versus universal
is shown in Fig. 3 (i.e., universal at the origin) with a
90 % confidence ellipse depicted. The distribution
of 1000 simulations shown in Fig. 3 shows 76.8 %
of simulations occur below the willingness to
accept threshold of at least €90,000/LYL in the
South West quadrant.
Scenario analysis
Long term effect of vaccination - Incremental cost-effectiveness
ratios
When the model incorporates the effect of the vaccine on
TB health states over 25 years, the ICERs for the universal
and selective based strategies compared to not vaccinating
are €167,878/LYG and €108,449/LYG respectively.
Table 3 Estimated number of cases (cases averted) in the three strategies over 15 years
Outcomes BCGuniversal (cases averted) BCGselective (cases averted) BCGno vacc
Pulmonary TB 21.6 (31.4) 47.1 (5.9) 53.0
Extrapulmonary TB 6.6 (13.5) 17.6 (2.5) 20.1
TB meningitis 1.4 (1.9) 2.9 (0.4) 3.3
Total 29.6 (46.8) 67.6 (8.8) 76.4
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Vaccinating a birth cohort-the societal perspective
When the model incorporates the indirect costs of par-
ents time off work, due to a TB related illness or a vac-
cine related adverse event, the ICERs for the universal
and selective based strategies compared to not vaccinat-
ing are €204,966/LYG and €143,468/LYG respectively,
which are comparable to the ICERs calculated in the
base case analysis. A similar trend was observed to the
base case analysis when moving from a universal to a se-
lective based strategy.
Discussion
The results of this economic evaluation suggest that
both the universal BCG vaccination programme and the
targeted strategy of selectively vaccinating high-risk neo-
nates in Ireland would not be considered cost effective
compared to not vaccinating. When compared to the
universal programme, the targeted (or selective) strategy
is substantially less expensive but demonstrates margin-
ally less health gain (4.8 life years). Assuming however,
that people demand twice the amount of money to relin-
quish one unit of health, compared to the amount they
are willing to pay to gain an extra unit of health [42],
the probabilistic analysis indicates that a move from a
universal based strategy to a selective based strategy
could be deemed acceptable.
While TB incidence has fallen dramatically in Western
Europe and the US over the last century it remains a
public health burden of global concern. Historically,
Ireland has had high rates of TB compared with other
countries in Western Europe but rates have been falling
and it is now considered a low-burden country. How-
ever, public concern about TB remains. Results from our
re-evaluation of vaccine efficacy confirm the protective
effect of the vaccine in the local population, as
demonstrated through studies conducted in Ireland in
the late 80’s and early 90’s [43–52]. The addition of our
estimates of vaccine efficacy to previously published sys-
tematic reviews and meta-analyses adds to the literature
on the efficacy of BCG vaccine, an area which has been
under-served and remains controversial. While decisions
in this area have been largely taken in Europe, these
questions remain to be considered in low resource coun-
tries with poor health infrastructures. The efficacy data
presented, which combines data from a country with a
previously high prevalence of TB to that of the inter-
national literature, will be a helpful and useful addition
for economic analysis in those settings.
Decrementally cost-effective medical interventions
With healthcare expenditures growing at a significant
rate, decision makers struggle with reconciling their fi-
nite budgets with the reimbursement of innovative med-
ical technologies, be they vaccines, pharmaceuticals or
diagnostics. In such situations, cost-saving alternatives
may become attractive, even if they come with reduced
benefits. The theory is that limited benefits could be
sacrificed for substantial resource savings, thus permit-
ting reallocation to higher value alternatives. TB control
is an area where this might be an appropriate approach,
especially in low-burden countries. Targeting vaccina-
tions to high-risk groups would allow re-allocation of re-
sources into more robust TB screening and treatment
programs. Less expensive, lower quality innovations are
ubiquitous in other markets but have not been described
in the health care sector to any great extent. However,
Nelson and colleagues [53] systematically identified and
quantified decrementally cost-effective health care inno-
vations, for instance, those where the monetary savings
had to be large enough to justify the associated QALY
Table 4 Estimated direct costs (costs avoided) in the vaccination strategies
Direct treatment costs (avoided) BCGuniversal (costs avoided) BCGselective (costs avoided) BCGno vaccination
Pulmonary TB €359,205 (€521,200) €781,507 (€98,898) €880,405
Extrapulmonary TB €136,539 (€279,738) €363,197 (€53,080) €416,277
TB meningitis €33,666 (€47,262) €71,960 (€8,968) €80,928
Total €529,410 (€848,199) €1,216,664 (€160,945) €1,377,609
Table 5 Baseline incremental cost effectiveness ratios of the three vaccination strategies
Costs Life Years Δ Costs Δ Life Years Gained (LFG) ICER (vs no vaccination)
No vaccination €1,108,208 20110.0
Selective €1,270,131 20111.2 €161,924 1.1 €143,233
Universal €2,325,823 20116.9 €1,217,616 5.9 €204,373
Costs Life Years Δ Costs Δ LYG
Selective €1,270,131 20111.2
Universal €2,325,823 20116.9 −€1,055,692 −4.8 Selective strategy less costly
& less effective
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Fig. 3 Incremental costs and LYG for the selective versus the universal vaccination strategy showing the 90 % confidence ellipse
Fig. 2 Tornado diagram depicting parameters of greatest influence in moving from a universal to a selective based strategy (Uni: universal,
Sel: selective)
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loss, i.e., those in the southwest quadrant of the cost-
effectiveness plane. To do this they conservatively desig-
nated an intervention as decrementally cost-effective if it
saved at least $100,000 for each QALY lost. This was
based on the existing available data which suggested that
people ‘demand’ 2 to 6 fold more per QALY lost than
they are willing to ‘pay’ for each QALY [42, 54]. On the
basis of this, results from our study would suggest that
to move from a universal vaccination strategy to a se-
lective based strategy saves approximately €218,692 per
life year lost. Indeed, assuming a willingness to accept
threshold of twice the willingness to pay threshold, the
probability of such a policy change being cost effective is
in the region of 77 %. This finding will be of interest to
other health-care systems who are transitioning from a
TB high-burden to a TB low-burden society in an era of
evidence-based health policy decision making. For policy
makers in Ireland, an appropriate next step would be to
consider the practical elements of implementing and
conducting such a vaccination policy, as successful TB
control in low burden countries requires efforts to iden-
tify the high risk groups among the population and en-
gage them in screening. This must happen along with
rigorous implementation of treatment strategies for
cases such as directly observed therapy (DOTs), along
with active case finding through contract tracing, to
ensure that the health system is able to diagnose and
manage cases, regardless of risk factors, as early as
possible. Indeed, in order to identify the most optimal
and efficient programme to use in the Irish healthcare
system, it would be prudent to compare the cost ef-
fectiveness of a screening and treatment programme vs
a programme of vaccination. However, the current TB
control programme would have to be standardised na-
tionally, in order that such an evaluation could make a
meaningful contribution to aid the decision maker.
Ethical considerations
Adopting such a change in vaccination policy also
raises some ethical implications. It is likely that there
will be an increase in TB cases as a result of changing
from universal to selective vaccination in Ireland. It is
important therefore that the message is communicated
clearly so as to maintain public trust in the vaccination
programme. A clearly communicated definition and ra-
tionale for classifying high and low risk infants would
also be needed in order to target the correct infants
and to help gain consent from parents for vaccination
of their children.
Strengths and limitations / Assumptions used
Identifying the target group for selective vaccination
For the purposes of this analysis, target group of high
risk infants for vaccination were assumed to be those
whose families have immigrated from high-incidence
countries. In Ireland this is likely to be the largest group
of “at risk” infants and data from the Growing Up in
Ireland study [7] was used to help quantify this param-
eter. There will be considerable uncertainty with the
figure used here (11.7 % of the birth cohort) as data
from some local health offices around the Dublin area
showed that for the latter half of 2012 and early 2013,
there was considerable variation in the proportion of
high risk infants (out of all those vaccinated) brought for
BCG vaccination. These figures ranged from 11.8 % in
some areas to 47.6 % in other areas (NIO, personal
communication). These figures were, however, highly
dependent on the clinic location and it is likely that the
higher figures will be over estimates. Other age groups
not considered in the analysis were children between
the ages of one to 16, who were previously unvaccin-
ated, and came from “high risk” families, as were previ-
ously unvaccinated under 16 year olds, who were born
or lived for prolonged periods in a high endemic area, as
it was difficult to quantify these groups. However they are
not considered to be the largest “high-risk” group.
Quality of life
This study did not incorporate a quality of life meas-
urement into the analysis. There is currently a paucity
of data in the literature on the quality of life in chil-
dren, probably due to the absence of an appropriate
quality of life instrument. As stipulated in the recent
NICE clinical guideline on tuberculosis [55], a study is
needed to ascertain quality-of-life score estimates from
those with TB (both active disease and latent infection),
including adverse treatment effects, using an appropriate
quality-of-life instrument. Cost-effectiveness estimates in
the form of QALYs would be more comparable with cost-
effectiveness estimates from other assessments of vaccines
and could assist in improving economic decision-making
throughout TB care. However, the incorporation of LYG
as the outcome measure does facilitate its comparison
with assessments conducted previously by this group (e.g.,
PCV7 [56], HPV [57], Hepatitis B [58] and rotavirus [59]).
Uncertainty
The results of the analysis are subject to some uncer-
tainty. One way sensitivity analysis indicates that the
ICERs are sensitive to the estimate of vaccine efficacy
against deaths. This is in keeping with the evidence from
the literature. There is also uncertainty associated with
the multiplier which apportions a level of risk to the tar-
geted (i.e., selective) population. In the absence of any
definitive evidence on the level of risk in the selective
population, the assumption is based on the TB rates in
the foreign born population relative to the indigenous
population.
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Conclusion
The results of the current study (i) support the protect-
ive effect of the BCG vaccine in infants and (ii) suggest
that a move from the universal to a selective based strat-
egy could be considered decrementally cost-effective and
may offer an opportunity to improve the efficiency of
health resource allocation, whereby the resources saved
could be applied to specific areas targeted in the national
TB control and prevention programme. The results of
this study will be of interest to those who are tasked
with resource planning and will serve as a beneficial case
study for those emerging economies with limited health
resources, who are working towards lowering the inci-
dence of TB in their country.
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